The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
10.1111/acel.12344 · doi-reference
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?
10.1002/jbmr.262 · doi-reference
Estrogen and the skeleton
10.1016/j.tem.2012.03.008 · doi-reference
FRAX and the assessment of fracture probability in men and women from the UK
10.1007/s00198-007-0543-5 · doi-reference
Senolytics improve physical function and increase lifespan in old age
10.1038/s41591-018-0092-9 · doi-reference
Senolytic drugs: from discovery to translation
10.1111/joim.13141 · doi-reference
Characterization of human senescent cell biomarkers for clinical trials
10.1111/acel.14489 · doi-reference
Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study
10.1016/j.ebiom.2018.12.052 · doi-reference
Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus quercetin in individuals with diabetic kidney disease
10.1016/j.ebiom.2019.08.069 · doi-reference
Targeted reduction of senescent cell burden alleviates focal radiotherapy-related bone loss
10.1002/jbmr.3978 · doi-reference
Targeted clearance of p21- but not p16-positive senescent cells prevents radiation-induced osteoporosis and increased marrow adiposity
10.1111/acel.13602 · doi-reference
Osteochondroprogenitor cells and neutrophils expressing p21 and senescence markers modulate fracture repair
10.1172/jci179834 · doi-reference
Local senolysis in aged mice only partially replicates the benefits of systemic senolysis
10.1172/jci162519 · doi-reference
The role of cellular senescence in ageing and endocrine disease
10.1038/s41574-020-0335-y · doi-reference
Cellular senescence in bone
10.1016/j.bone.2019.01.015 · doi-reference
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities
10.1172/jci64098 · doi-reference
Hallmarks of aging: an expanding universe
10.1016/j.cell.2022.11.001 · doi-reference
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
10.1038/ncb1909 · doi-reference
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor
10.1371/journal.pbio.0060301 · doi-reference
Aging, cellular senescence, and cancer
10.1146/annurev-physiol-030212-183653 · doi-reference
Cellular senescence: a key therapeutic target in aging and diseases
10.1172/jci158450 · doi-reference
Cellular senescence: defining a path forward
10.1016/j.cell.2019.10.005 · doi-reference
The serial cultivation of human diploid cell strains
10.1016/0014-4827(61)90192-6 · doi-reference
Type 2 diabetes and fracture risk in older women
10.1001/jamanetworkopen.2024.25106 · doi-reference
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis
10.1007/s00198-006-0253-4 · doi-reference
Older women with diabetes have an increased risk of fracture: a prospective study
10.1210/jcem.86.1.7139 · doi-reference
Mechanisms of diabetes mellitus-induced bone fragility
10.1038/nrendo.2016.153 · doi-reference
Type 2 diabetes mellitus and bone
10.1111/joim.12725 · doi-reference
Type 2 diabetes and the skeleton: new insights into sweet bones
10.1016/s2213-8587(15)00283-1 · doi-reference
Determinants of bone strength and quality in diabetes mellitus in humans
10.1016/j.bone.2015.07.027 · doi-reference
Deconstructing senescence phenotypes in cells of the bone and bone marrow
10.1172/jci204645 · doi-reference
Aged murine bone marrow myeloid and mesenchymal cells develop unique senescence phenotypes
10.1172/jci195772 · doi-reference
Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids
10.1074/jbc.m702810200 · doi-reference
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
10.1016/s0140-6736(17)31613-6 · doi-reference
Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials
10.1007/s00198-024-07049-w · doi-reference
Romosozumab or alendronate for fracture prevention in women with osteoporosis
10.1056/nejmoa1708322 · doi-reference
One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study
10.1002/jbmr.3622 · doi-reference
Romosozumab treatment in postmenopausal women with osteoporosis
10.1056/nejmoa1607948 · doi-reference
Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial
10.1002/jbmr.4457 · doi-reference
Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment
10.1002/jbmr.3735 · doi-reference
